Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Presentations

News

News

  • Press Releases
  • Presentations
  • Events
2016 ASH Poster - Inhibition of c-Myc by APTO-253 as an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

2016 ASH Poster - Inhibition of c-Myc by APTO-253 as an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Dec 3, 2016
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
© 2023 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences